Symbols / ANTX Stock $4.68 +2.86% AN2 Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
ANTX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Eric E. Easom
Exch · Country NMS · United States
Market Cap 168.46M
Enterprise Value 110.20M
Income -35.17M
Sales —
FCF (ttm) -18.38M
Book/sh 1.94
Cash/sh 1.61
Employees 21
Insider 10d —
IPO Mar 25, 2022
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -5.85
PEG —
P/S —
P/B 2.42
P/C —
EV/EBITDA —
EV/Sales —
Quick Ratio 6.75
Current Ratio 6.87
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -1.16
EPS next Y -0.80
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-17
Earnings (prior) 2026-03-17
ROA -30.93%
ROE -52.14%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 36.00M
Shs Float 16.98M
Insider Own 19.96%
Instit Own 51.36%
Short Float 2.11%
Short Ratio 1.52
Short Interest 633.93K
52W High 6.91
vs 52W High -32.27%
52W Low 1.00
vs 52W Low 368.00%
Beta -1.32
Impl. Vol. —
Rel Volume 0.07
Avg Volume 1.45M
Volume 105.46K
Target (mean) $1.00
Tgt Median $1.00
Tgt Low $1.00
Tgt High $1.00
# Analysts 1
Recom None
Prev Close $4.55
Price $4.68
Change 2.86%
About

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases; and GSK plc for the development of new therapies for TB. AN2 Therapeutics, Inc. was incorporated in 2017 and is headquartered in Menlo Park, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$1.00
Mean price target
2. Current target
$4.68
Latest analyst target
3. DCF / Fair value
$-9.19
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.68
Low
$1.00
High
$1.00
Mean
$1.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-05-05 main JMP Securities Market Outperform → Market Outperform $2
2025-03-26 reit Citizens Capital Markets Market Outperform → Market Outperform $5
2025-02-25 reit Citizens Capital Markets Market Outperform → Market Outperform $5
2025-02-03 reit JMP Securities Market Outperform → Market Outperform $5
2024-11-19 reit JMP Securities Market Outperform → Market Outperform $5
2024-11-18 down TD Cowen Buy → Hold —
2024-08-09 main JMP Securities Market Outperform → Market Outperform $3
2024-07-03 up Leerink Partners Market Perform → Outperform —
2024-05-16 main Evercore ISI Group In-Line → In-Line $2
2024-04-02 up JMP Securities Market Perform → Market Outperform $6
2024-04-01 reit Oppenheimer Perform → Perform —
2024-02-13 down Leerink Partners Outperform → Market Perform $7
2024-02-12 down Evercore ISI Group Outperform → In-Line $7
2024-02-12 down Oppenheimer Outperform → Perform —
2024-02-12 down JMP Securities Market Outperform → Market Perform —
2024-01-04 init JMP Securities — → Market Outperform $30
2023-03-30 main Oppenheimer — → Outperform $24
2022-11-14 main SVB Leerink — → Outperform $25
2022-04-19 init Evercore ISI Group — → Outperform $25
2022-04-19 init Oppenheimer — → Outperform $22
News
RSS: Latest ANTX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-10 MARKS GILBERT LYNN Director — 3,775 $0.00 $0
2026-04-10 MARTIN PATRICIA A Director — 1,192 $0.00 $0
2026-04-10 AZIZ KABEER Director — 3,775 $0.00 $0
2026-02-20 CHANDA SANJAY Officer — 38,000 $0.00 $0
2026-02-20 DAY LUCY O. Chief Financial Officer — 38,000 $0.00 $0
2026-02-20 EASOM ERIC Chief Executive Officer — 112,250 $0.00 $0
2026-02-20 EIZEN JOSHUA M Chief Operating Officer — 50,000 $0.00 $0
2026-01-12 MARKS GILBERT LYNN Director — 11,560 $0.00 $0
2026-01-12 MARTIN PATRICIA A Director — 3,650 $0.00 $0
2026-01-12 AZIZ KABEER Director — 11,560 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
38.11
-30.14%
54.55
-21.66%
69.64
+64.77%
42.26
Research And Development
24.77
-38.82%
40.49
-26.21%
54.87
+85.93%
29.51
Selling General And Administration
13.34
-5.16%
14.07
-4.73%
14.76
+15.79%
12.75
General And Administrative Expense
13.34
-5.16%
14.07
-4.73%
14.76
+15.79%
12.75
Other Gand A
13.34
-5.16%
14.07
-4.73%
14.76
+15.79%
12.75
Total Expenses
38.11
-30.14%
54.55
-21.66%
69.64
+64.77%
42.26
Operating Income
-38.11
+30.14%
-54.55
+21.66%
-69.64
-64.77%
-42.26
Total Operating Income As Reported
-38.11
+32.89%
-56.79
+18.45%
-69.64
-64.77%
-42.26
EBITDA
-38.11
+30.14%
-54.55
+21.66%
-69.64
-64.77%
-42.26
Normalized EBITDA
-38.11
+27.16%
-52.32
+24.87%
-69.64
-64.77%
-42.26
EBIT
-38.11
+30.14%
-54.55
+21.66%
-69.64
-64.77%
-42.26
Total Unusual Items
0.00
+100.00%
-2.23
0.00
—
Total Unusual Items Excluding Goodwill
0.00
+100.00%
-2.23
0.00
—
Special Income Charges
0.00
+100.00%
-2.23
0.00
—
Restructuring And Mergern Acquisition
0.00
-100.00%
2.23
0.00
—
Net Income
-35.17
+31.46%
-51.32
+20.72%
-64.73
-58.05%
-40.96
Pretax Income
-35.17
+31.46%
-51.32
+20.72%
-64.73
-58.05%
-40.96
Net Non Operating Interest Income Expense
2.93
-46.32%
5.47
+12.47%
4.86
+259.73%
1.35
Net Interest Income
2.93
-46.32%
5.47
+12.47%
4.86
+259.73%
1.35
Interest Income Non Operating
2.93
-46.32%
5.47
+12.47%
4.86
+259.73%
1.35
Interest Income
2.93
-46.32%
5.47
+12.47%
4.86
+259.73%
1.35
Other Income Expense
0.00
+100.04%
-2.23
-5293.02%
0.04
-96.71%
1.31
Other Non Operating Income Expenses
0.00
+0.00%
0.00
-97.67%
0.04
-96.71%
1.31
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-35.17
+31.46%
-51.32
+20.72%
-64.73
-58.05%
-40.96
Net Income From Continuing Operation Net Minority Interest
-35.17
+31.46%
-51.32
+20.72%
-64.73
-58.05%
-40.96
Net Income From Continuing And Discontinued Operation
-35.17
+31.46%
-51.32
+20.72%
-64.73
-58.05%
-40.96
Net Income Continuous Operations
-35.17
+31.46%
-51.32
+20.72%
-64.73
-58.05%
-40.96
Normalized Income
-35.17
+28.34%
-49.09
+24.17%
-64.73
-58.05%
-40.96
Net Income Common Stockholders
-35.17
+31.46%
-51.32
+20.72%
-64.73
-51.33%
-42.78
Otherunder Preferred Stock Dividend
—
—
—
—
Diluted EPS
—
-1.72
+37.23%
-2.74
+1.79%
-2.79
Basic EPS
—
-1.72
+37.23%
-2.74
+1.79%
-2.79
Basic Average Shares
—
29.83
+26.39%
23.60
+53.85%
15.34
Diluted Average Shares
—
29.83
+26.39%
23.60
+53.85%
15.34
Diluted NI Availto Com Stockholders
-35.17
+31.46%
-51.32
+20.72%
-64.73
-51.33%
-42.78
Preferred Stock Dividends
—
—
—
1.82
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
61.95
-32.73%
92.09
-33.63%
138.74
+35.28%
102.56
Current Assets
59.94
-30.52%
86.26
-21.94%
110.51
+12.05%
98.62
Cash Cash Equivalents And Short Term Investments
58.00
-30.64%
83.62
-22.07%
107.30
+11.70%
96.06
Cash And Cash Equivalents
19.94
-6.60%
21.35
+36.45%
15.65
-42.51%
27.22
Cash Equivalents
—
—
4.48
-55.89%
10.15
Cash Financial
—
—
11.17
-34.56%
17.07
Other Short Term Investments
38.06
-38.88%
62.27
-32.06%
91.65
+33.13%
68.84
Prepaid Assets
—
—
—
—
Other Current Assets
1.94
-26.78%
2.64
-17.68%
3.21
+25.37%
2.56
Total Non Current Assets
2.01
-65.44%
5.83
-79.37%
28.24
+616.86%
3.94
Investments And Advances
2.01
-59.91%
5.02
-81.54%
27.19
+744.80%
3.22
Non Current Deferred Assets
—
—
—
0.00
Other Non Current Assets
—
0.80
-22.91%
1.04
+44.86%
0.72
Total Liabilities Net Minority Interest
8.89
-13.17%
10.24
-27.10%
14.04
+95.37%
7.19
Current Liabilities
8.72
-14.83%
10.24
-27.10%
14.04
+95.42%
7.19
Payables And Accrued Expenses
5.07
-34.72%
7.77
-16.95%
9.36
+88.69%
4.96
Payables
3.02
-8.92%
3.32
+23.95%
2.68
+26.11%
2.12
Accounts Payable
3.02
-8.92%
3.32
+23.95%
2.68
+26.11%
2.12
Current Accrued Expenses
2.05
-53.93%
4.45
-33.33%
6.68
+135.50%
2.84
Pensionand Other Post Retirement Benefit Plans Current
2.42
+44.27%
1.68
-58.29%
4.02
+85.33%
2.17
Current Debt And Capital Lease Obligation
—
—
—
0.05
Current Capital Lease Obligation
—
—
0.00
-100.00%
0.05
Other Current Liabilities
1.23
+55.37%
0.79
+18.41%
0.67
+11033.33%
0.01
Total Non Current Liabilities Net Minority Interest
0.17
0.00
0.00
-100.00%
0.00
Other Non Current Liabilities
0.17
—
—
—
Preferred Securities Outside Stock Equity
—
—
—
—
Stockholders Equity
53.06
-35.17%
81.85
-34.36%
124.70
+30.75%
95.37
Common Stock Equity
53.06
-35.17%
81.85
-34.36%
124.70
+30.75%
95.37
Capital Stock
0.00
0.00
0.00
0.00
Common Stock
0.00
0.00
0.00
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
27.41
-8.38%
29.92
+0.60%
29.74
+53.29%
19.40
Ordinary Shares Number
27.41
-8.38%
29.92
+0.60%
29.74
+53.29%
19.40
Additional Paid In Capital
293.95
+2.21%
287.59
+3.12%
278.88
+50.37%
185.47
Retained Earnings
-240.95
-17.09%
-205.78
-33.23%
-154.46
-72.15%
-89.72
Gains Losses Not Affecting Retained Earnings
0.06
+83.87%
0.03
-88.73%
0.28
+173.53%
-0.37
Other Equity Adjustments
0.06
+83.87%
0.03
-88.73%
0.28
+173.53%
-0.37
Total Equity Gross Minority Interest
53.06
-35.17%
81.85
-34.36%
124.70
+30.75%
95.37
Total Capitalization
53.06
-35.17%
81.85
-34.36%
124.70
+30.75%
95.37
Working Capital
51.22
-32.63%
76.02
-21.19%
96.46
+5.50%
91.44
Invested Capital
53.06
-35.17%
81.85
-34.36%
124.70
+30.75%
95.37
Total Debt
—
—
0.00
-100.00%
0.05
Capital Lease Obligations
—
—
0.00
-100.00%
0.05
Net Tangible Assets
53.06
-35.17%
81.85
-34.36%
124.70
+30.75%
95.37
Tangible Book Value
53.06
-35.17%
81.85
-34.36%
124.70
+30.75%
95.37
Available For Sale Securities
2.01
-59.91%
5.02
-81.54%
27.19
+744.80%
3.22
Derivative Product Liabilities
—
—
0.00
-100.00%
0.00
Investmentin Financial Assets
2.01
-59.91%
5.02
-81.54%
27.19
+744.80%
3.22
Preferred Stock Equity
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-29.83
+39.43%
-49.26
+7.56%
-53.29
-59.25%
-33.46
Cash Flow From Continuing Operating Activities
-29.83
+39.43%
-49.26
+7.56%
-53.29
-59.25%
-33.46
Net Income From Continuing Operations
-35.17
+31.46%
-51.32
+20.72%
-64.73
-58.05%
-40.96
Other Non Cash Items
—
—
0.05
-31.17%
0.08
Stock Based Compensation
6.25
-25.09%
8.34
-0.88%
8.41
+91.57%
4.39
Change In Working Capital
0.16
+105.48%
-3.00
-151.34%
5.83
+56.91%
3.72
Change In Prepaid Assets
1.51
+87.36%
0.81
+178.65%
-1.03
+38.86%
-1.68
Change In Payables And Accrued Expense
-1.96
+50.20%
-3.93
-162.88%
6.25
+14.14%
5.47
Change In Accrued Expense
-1.66
+63.67%
-4.57
-180.24%
5.69
+91.33%
2.98
Change In Payable
-0.30
-146.18%
0.64
+15.91%
0.55
-77.85%
2.50
Change In Account Payable
-0.30
-146.18%
0.64
+15.91%
0.55
-77.85%
2.50
Change In Other Working Capital
—
—
—
1.25
Change In Other Current Assets
—
—
—
-0.72
Change In Other Current Liabilities
0.61
+382.54%
0.13
-79.45%
0.61
+896.10%
-0.08
Investing Cash Flow
28.31
-48.14%
54.59
+226.14%
-43.28
-98.79%
-21.77
Cash Flow From Continuing Investing Activities
28.31
-48.14%
54.59
+226.14%
-43.28
-98.79%
-21.77
Net Investment Purchase And Sale
28.31
-48.14%
54.59
+226.14%
-43.28
-98.79%
-21.77
Purchase Of Investment
-46.19
+1.20%
-46.75
+64.63%
-132.18
-40.86%
-93.84
Sale Of Investment
74.50
-26.49%
101.34
+13.99%
88.90
+23.36%
72.06
Financing Cash Flow
0.11
-69.62%
0.37
-99.56%
84.99
+20.81%
70.36
Cash Flow From Continuing Financing Activities
0.11
-69.62%
0.37
-99.56%
84.99
+20.81%
70.36
Net Common Stock Issuance
—
0.00
-100.00%
84.53
+20.13%
70.37
Proceeds From Stock Option Exercised
0.11
-69.62%
0.37
-20.00%
0.47
+4327.27%
-0.01
Net Other Financing Charges
—
—
—
-0.01
Changes In Cash
-1.41
-124.72%
5.70
+149.29%
-11.57
-176.52%
15.12
Beginning Cash Position
21.35
+36.45%
15.65
-42.51%
27.22
+125.01%
12.10
End Cash Position
19.94
-6.60%
21.35
+36.45%
15.65
-42.51%
27.22
Free Cash Flow
-29.83
+39.43%
-49.26
+7.56%
-53.29
-59.25%
-33.46
Amortization Of Securities
-1.07
+67.37%
-3.28
-14.85%
-2.85
-312.57%
-0.69
Common Stock Issuance
—
0.00
-100.00%
84.53
+20.13%
70.37
Issuance Of Capital Stock
—
0.00
-100.00%
84.53
+20.13%
70.37
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category